GlassScriptPhysician profile
Breeanna Gibson
NPI 1588824635
$4,133.23
in general payments reported to CMS, 2019-2025
33 companies · $833 in 2025
The $833 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $243 · 2021: $537 · 2022: $667 · 2023: $790 · 2024: $541 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.10 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.14 | 2019-2023 | |
| Astellas Pharma US INC | $476.56 | 2020-2025 | Veozah, Myrbetriq |
| Organon LLC | $467.41 | 2021-2025 | Nexplanon, Nuvaring |
| Mayne Pharma Commercial LLC | $456.46 | 2022-2025 | |
| Medtronic, INC. | $283.79 | 2025 | Ligasure |
| Bayer Healthcare Pharmaceuticals INC. | $209.45 | 2019-2023 | |
| Hologic Sales and Service, LLC | $172.92 | 2020-2025 | Thinprep 2000 Processor, Aptima |
| Amgen INC. | $143.16 | 2019-2024 | Evenity, Prolia |
| Radius Health, INC. | $141.50 | 2019-2024 | Tymlos |
| Agile Therapeutics, INC. | $85.72 | 2021-2023 | Twirla |
| Sage Therapeutics, LLC | $75.18 | 2021-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $75.00 | 2019-2021 | |
| Avion Pharmaceuticals | $72.67 | 2019-2021 | |
| Myriad Women'S Health, INC. | $64.13 | 2023 | Myrisk |
| Coopersurgical, INC. | $54.26 | 2020-2025 | Paragard T 380a |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $54.14 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $48.39 | 2025 | Myfembree |
| Pfizer INC. | $44.55 | 2019-2021 | |
| Allergan, INC. | $42.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.66 | 2020-2021 | |
| Roche Diagnostics Corporation | $34.33 | 2019 | |
| Millicent US INC | $29.33 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Conmed Corporation | $27.08 | 2025 | Airseal |
| Amag Pharmaceuticals, INC. | $22.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $20.23 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.16 | 2024 | Monoferric |
| Baudax Bio INC. | $16.40 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.23 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.15 | 2022 | |
| Davol INC. | $12.83 | 2023 | Channel Drain |
| Acessa Health INC. | $12.54 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11.31 | 2020 | |
| Meditrina | $11.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breeanna Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.